Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-05-31
2005-05-31
Park, Hankyel T. (Department: 1648)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S325000, C424S009340, C424S192100
Reexamination Certificate
active
06900035
ABSTRACT:
This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g., cells from cervical and other tumors). The HPV protein can be joined to a stress protein by chemical conjugation or noncovalently using linking moieties, or by fusion (e.g., a recombinant fusion protein). Also described are expression vectors containing sequences encoding HPV antigens and stress proteins, which can be introduced into cells of a subject or cells ex vivo. Also described are compositions that include a stress protein linked to an HPV antigen and another pharmacologically acceptable component and stress protein—HPV antigen fusions and conjugates. These compositions can be used to induce or enhance an immune response against HPV and cells that exhibit HPV antigens, including HPV-associated tumors.
REFERENCES:
patent: 4716038 (1987-12-01), Stanford et al.
patent: 4724144 (1988-02-01), Rook et al.
patent: 4918166 (1990-04-01), Kingsman et al.
patent: 5114844 (1992-05-01), Cohen et al.
patent: 5348945 (1994-09-01), Berberian et al.
patent: 5504005 (1996-04-01), Bloom et al.
patent: 5578300 (1996-11-01), Schmidt et al.
patent: 5580563 (1996-12-01), Tam
patent: 5599545 (1997-02-01), Stanford et al.
patent: 5736146 (1998-04-01), Cohen et al.
patent: 5750119 (1998-05-01), Srivastava
patent: 5830464 (1998-11-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: 5858368 (1999-01-01), Smith et al.
patent: 5935576 (1999-08-01), Srivastava
patent: 5948646 (1999-09-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5985270 (1999-11-01), Srivastava
patent: 5997873 (1999-12-01), Srivastava
patent: 6007806 (1999-12-01), Lathe et al.
patent: 6007821 (1999-12-01), Srivastava et al.
patent: 6017540 (2000-01-01), Srivastava et al.
patent: 6017544 (2000-01-01), Srivastava
patent: 6030618 (2000-02-01), Srivastava
patent: 6048530 (2000-04-01), Srivastava
patent: 6130087 (2000-10-01), Srivastava et al.
patent: 6136315 (2000-10-01), Srivastava
patent: 6139841 (2000-10-01), Srivastava
patent: 6143299 (2000-11-01), Srivastava
patent: 6156302 (2000-12-01), Srivastava
patent: 6162436 (2000-12-01), Srivastava
patent: 6168793 (2001-01-01), Srivastava
patent: 6187312 (2001-02-01), Srivastava
patent: 6322790 (2001-11-01), Srivastava
patent: 6335183 (2002-01-01), Young et al.
patent: 6338952 (2002-01-01), Young et al.
patent: 0 262 710 (1988-04-01), None
patent: 0 322 990 (1989-07-01), None
patent: 2 251 186 (1992-07-01), None
patent: WO 85/05034 (1985-11-01), None
patent: WO 88/00974 (1988-02-01), None
patent: WO 88/05823 (1988-08-01), None
patent: WO 88/06591 (1988-09-01), None
patent: WO 89/12455 (1989-12-01), None
patent: WO 90/15873 (1990-12-01), None
patent: WO 91/02542 (1991-03-01), None
patent: WO 91/15572 (1991-10-01), None
patent: WO 92/08484 (1992-05-01), None
patent: WO 92/08488 (1992-05-01), None
patent: WO 93/17712 (1993-09-01), None
patent: WO 94/03208 (1994-02-01), None
patent: WO 94/29459 (1994-12-01), None
patent: WO 95/24923 (1995-09-01), None
patent: WO 95 31994 (1995-11-01), None
patent: WO 96/10421 (1996-04-01), None
patent: WO 96 19496 (1996-06-01), None
patent: WO 96 26277 (1996-08-01), None
patent: WO 97 06821 (1997-02-01), None
patent: WO 9710000 (1997-03-01), None
patent: WO 97/26910 (1997-07-01), None
patent: WO 98/23735 (1998-06-01), None
patent: WO 98/35705 (1998-08-01), None
K. Suzue et al., “Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24”,J. of Immunology, 156: 873-879 (1996).
T. De Gruijl et al., “T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection”,J. of General Virology, 77:2183-2191 (1996).
Hungarian Patent Office Novelty Search Report dated Sep. 12, 2002.
International Search Report (Application No.: PCT/CA 98/00246) dated Sep. 30, 1998.
Agranovsky et al., “Putative 65 kDa Protein of Beet Yellows Closterovirus Is a Homologue of HSP70 Heat Shock Proteins,” J. Mol. Biol., 217:603-610 (1991).
Ardeshir et al., “A 75 Kd Merozoite Surface Protein of Plasmodium Falciparum which is Related to the 70 kd Heat-Shcok Proteins,” Embo J., 6(2):493-499 (1987).
Arnosti et al., “Characterization of heat shock in Bacillus subtilis ,” J. Bact., 168(3):1243-1249 (Dec. 1986).
Arrigo and Welch, “Characterization and Purification of the Small 28,000-Dalton Mammalian Heat Shock Protein”, J. Biol. Chem., 262(32):15359-15369 (1987).
Barrios et al., “Heat shock proteins as carrier molecules: in vivo helper effect mediated byEscherichia coliGroEL and DnaK proteins requires cross-linking with antigen,” Clin. Exp. Immunol., 98:229-233 (1994).
Barrios et al., “Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming,” Eur. J. Immunol., 22:1365-1372 (1992).
Beech et al., “CD4+ Th2 cells specific for mycobacterial 65-kilodalton heat shock protein protect against pristane-induced arthritis,” J. Immunol. 159:3692-3697 (1997).
Bertelli et al., “BCG-Induced Resistance in Trypanosoma cruzi Experimental Infections,” Tropenmed Parasitol, 32:93-96 (1981).
Birk et al., “T-cell autoimmunity in type 1 diabetes mellitus,”Curr. Opin. Immunol., 5:903-909 (1993).
Blachere et al., “Heat Shock Protein-Peptide Complexes, Reconstituted in Vitro, Elicit Peptide-specific Cytotoxic T Lymphocyte Response and Tumor Immunity,” J. Exp. Med. 186(8):1315-1322 (Oct. 20, 1997).
Blander and Horwitz, “Major Cytoplasmic Membrane Protein of Legionella Pneumophila, a Genus Common Antigen and Member of the hsp 60 Family of Heat Shock Proteins, Induces Protective Immunity in a Guinea Pig Model of Legionnaires' Diseases,” J. Clin. Invest., 91:717-723 (1993).
Borysiewicz et al, “A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer,” LANCET, 347:1523-27 (1996).
Butini et al., “Comparative Analysis of HIV-specific CTL Activity in Lymphoid Tissue and Peripheral Blood,” J. Cell Biochem. Suppl. 18B Abstract J306 (1994).
Cain and Howett, “Preventing cervical cancer,” SCIENCE, 288:1753-54 (2000).
Cassell et al., “A Phase II Study on the Postsurgical Management of Stage Malignant Melanoma With a Newcastle Disease Virus Oncolysate,” CANCER, 52:856-860 (Sep. 1983).
Cassell et al., “Viral Oncolysate in the Management of Malignant Melanoma, I. Preparation of the Oncolysate and Measurement of Immunologic Responses” CANCER, 40:672-679 (Aug. 1977).
Catelli et al., “The common 90-kd protein component of non-transformed ‘8S’ steroid receptors is a heat-shock protein”, Embo J., 4(12):3131-3135 (1985).
Chandrasekhar et al., “Purification and Properties of the groES Morphogenetic Protein ofEscherichia coli”, J. Biol. Chem., 261(26):12414-12419 (1986).
Cohen et al., “Immunity to 60 kDa heat shock protein in autoimmune diabetes,” Diab. Nutr. Metab., 9(4):229-232 (1996).
Cohen, “Jitters jeopardize AIDS vaccine trials ,” SCIENCE, 262: 980-981 (1993).
Dahlseid et al., “PBP74, a new member of the mammalian 70-kDa heat shock protein family, is a mitochondrial protein,” Mol Biol Cell. 5(11):1265-1275 (1994).
De Velasco et al., “Synthetic Peptides Representing T-Cell Epitopes Act as Carriers in Pneumococcal Polysaccharide Conjugate Vaccines,” Infect. & Immun., 63:961-968 (1995).
Del Guidice, “Hsp70: a carrier molecule with built-in adjuvanticity,” EXPERIENTIA, 50:1061-1066 (1994).
Chu N. Randall
Mizzen Lee A.
Wu Huacheng Bill
Fish & Richardson P.C.
Park Hankyel T.
Stressgen Biotechnologies, Inc.
LandOfFree
Immune responses against HPV antigens elicited by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immune responses against HPV antigens elicited by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immune responses against HPV antigens elicited by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3377259